Nanoencapsulation of Natural Lipid-Modulating Agents for Obesity-Induced Dyslipidemia

Taliikwa Nicholas Ceaser

Department of Pharmacognosy Kampala International University Uganda

Email:ceaser.taliikwa@studwc.kiu.ac.ug

                                                                                       ABSTRACT
Obesity-induced dyslipidemia, typically characterized by elevated triglycerides, increased small dense LDL, and reduced HDL functionality, is a major mediator of cardiovascular risk in metabolic disease. Natural lipidmodulating agents such as polyphenols, phytosterols, omega-3–rich bioactives, terpenoids, and alkaloids can influence lipid absorption, hepatic lipogenesis, cholesterol transport, bile acid signaling, inflammation, and oxidative stress. However, clinical translation is often limited by poor aqueous solubility, chemical instability, variable intestinal absorption, extensive first-pass metabolism, and inconsistent tissue exposure, especially in the context of obesity-associated gut and hepatic dysfunction. Nanoencapsulation offers a formulation-driven strategy to improve solubilization, protect labile compounds, enhance mucosal residence, promote lymphatic uptake, and enable controlled or region-specific release. Lipid-based systems, polymeric nanoparticles, biopolymer matrices, micelles, and nanocrystals can increase exposure consistency and strengthen pharmacodynamic engagement of lipid metabolism pathways, including reductions in triglyceride-rich lipoproteins and improved hepatic lipid handling. Yet dyslipidemia requires chronic management; therefore, long-term safety, scalable manufacturing, and rigorous characterization are essential, as is clear PK–PD linkage to clinically meaningful endpoints such as triglycerides, apoB-containing lipoproteins, non-HDL cholesterol, and markers of hepatic steatosis and inflammation. This review evaluates nanoencapsulation strategies for natural lipid-modulating agents in obesity-induced dyslipidemia and highlights translational priorities for clinical adoption.

Keywords: dyslipidemia; obesity; nanoencapsulation; natural products; lipid metabolism.

CITE AS: Taliikwa Nicholas Ceaser (2026). Nanoencapsulation of Natural Lipid-Modulating Agents for Obesity-Induced Dyslipidemia. IDOSR JOURNAL OF SCIENTIFIC RESEARCH 11(2):77-84. https://doi.org/10.59298/IDOSRJSR/2026/11.2.7784